The global market for antibody-drug conjugates estimated to reach $90 billion by 2029, expanding at a double-digit CAGR of 35.5% over the forecast period, driven by increasing drug prices, and rapid approval of new treatments.
Antibody-drug conjugates (ADCs), which consist of a mAb chemically linked to a small-molecule therapeutics, are a niche class of drugs that offer promise, particularly as oncology drugs.
- ADCs are one of the fastest growing classes of oncology therapeutics. In the quest for more targeted therapies and potentially more clinically efficacious drugs, biopharmaceutical companies are increasing their research and product development in biologics.
- ADCs represent an innovative therapeutic application that combines the unique properties of monoclonal antibodies with the potent cell killing activity of cytotoxic bioactive compounds.
- Although the majority of this work is focused on monoclonal antibodies (mAbs) and recombinant proteins, progress is being made in specialized drug types.
- ADCs represent an innovative therapeutic application that combines the unique properties of monoclonal antibodies with the potent cell killing activity of cytotoxic bioactive compounds.
In 2011, US-FDA approved Seattle Genetics/Takeda’s Adcetris (brentuximab vedotin) for treating Hodgkin lymphoma and anaplastic large cell lymphoma, followed by, Roche’s Kadcyla (trastuzumab emtansine) approval in 2013 for the treatment of breast cancer.
- Advancements over the past several decades have led to a new generation of ADCs comprising non-immunogenic mAbs, linkers with balanced stability and highly potent cytotoxic agents.
- In the recent years, with the popularity and growth of ADC pipelines, companies have invested in the required supply chains for raw materials and services to support the highly specialized skills required for ADC containment, development, manufacturing, and analysis.
- With a number of ADCs in clinical development, the key question is whether ADCs will be able to fill a role in biopharmaceutical development. The future of ADCs in the biopharmaceutical market will ultimately depend on their clinical success.
- In the recent years, with the popularity and growth of ADC pipelines, companies have invested in the required supply chains for raw materials and services to support the highly specialized skills required for ADC containment, development, manufacturing, and analysis.
The global market for antibody drug conjugates research report provides market size ($million 2019 to 2029), market share analysis, growth trends and forecast (CAGR%, 2023 to 2029).
The global antibody drug conjugates market segmented by product [Adcetris (Brentuximab vedotin), Aidixi (Disitamab vedotin), Akalux (Cetuximab sarotalocan), Besponsa (Inotuzumab ozogamicin), Blenrep (Belantamab mafodotin), Enhertu (Trastuzumab deruxtecan), Kadcyla (Trastuzumab emtansine), Lumoxiti (Moxetumomab pasudotox), Mylotarg (Gemtuzumab ozogamicin), Padcev (Enfortumab vedotin), Polivy (Polatuzumab vedotin), Tivdak (Tisotumab vedotin), Trodelvy (Sacituzumab govitecan), Zynlonta (Loncastuximab tesirine), pipeline analysis (phase II and III) and geography.
- Based on marketed products, the Adcetris (brentuximab vedotin), an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE) segment accounted for the slightly larger share of market and anticipated to witness moderate growth rate during the forecast period.
- A large number of ongoing clinical trials (phase I – IV) are being conducted. Brentuximab vedotin is marketed as Adcetris by Seattle Genetics Inc. in North America and Takeda Oncology in the rest of the world.
- Among the pipeline products, the Rova-T (rovalpituzumab tesirine), a novel biomarker-specific ADC that is derived from cancer stem cells targeting the delta-like protein 3 (DLL3), dominated the market, whereas the IMGN853 (mirvetuximab soravtansine) segment expected to register fastest CAGR during the next few years.
- Rovalpituzumab tesirine currently in clinical trials to assess the safety and tolerability at different dose levels in patients with small cell lung cancer in progressed or recurred stage following standard chemotherapy.
- Mirvetuximab soravtansine is a FRα-targeting ADC comprising a folate receptor α (FRα)-binding antibody conjugated, via the hindered disulfide sulfo-SPDB linker, to the maytansinoid DM4, a potent cancer-cell killing agent developed by ImmunoGen.
- Rovalpituzumab tesirine currently in clinical trials to assess the safety and tolerability at different dose levels in patients with small cell lung cancer in progressed or recurred stage following standard chemotherapy.
The global market for antibody drug conjugates research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA) and Rest of the World.
In addition, the global ADC market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major competitors operating in the global antibody drug conjugates market and profiled in this report include ADC Therapeutics S.A., Astellas Pharma, Inc., AstraZeneca plc, Daiichi Sankyo Co. Ltd., Gilead Sciences, Inc. (Immunomedics, Inc.), GlaxoSmithKline plc, Innate Pharma S.A., Pfizer, Inc., Rakuten Medical, Inc., RemeGen Co., Ltd. (RemeGen Biosciences), Roche Holding AG, Seagen, Inc. (Seattle Genetics, Inc.), and Takeda Pharmaceutical Co. Ltd.
- Product
- Adcetris (Brentuximab vedotin)
- Aidixi (Disitamab vedotin)
- Akalux (Cetuximab sarotalocan)
- Besponsa (Inotuzumab ozogamicin)
- Blenrep (Belantamab mafodotin)
- Enhertu (Trastuzumab deruxtecan)
- Kadcyla (Trastuzumab emtansine)
- Lumoxiti (Moxetumomab pasudotox)
- Mylotarg (Gemtuzumab ozogamicin)
- Padcev (Enfortumab vedotin)
- Polivy (Polatuzumab vedotin)
- Tivdak (Tisotumab vedotin)
- Trodelvy (Sacituzumab govitecan)
- Zynlonta (Loncastuximab tesirine)
- Pipeline Analysis (Phase II and III)
- Geography
- North America (U.S., Canada)
- Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
- Asia Pacific (Japan, China, India, Rest of APAC)
- Latin America (Brazil, Mexico, Rest of LA)
- Rest of the World
- Company Profiles
- ADC Therapeutics S.A.
- Astellas Pharma, Inc.
- AstraZeneca plc
- Daiichi Sankyo Company Limited
- Gilead Sciences, Inc. (Immunomedics, Inc.)
- GlaxoSmithKline plc
- Innate Pharma S.A.
- Pfizer, Inc.
- Rakuten Medical, Inc.
- RemeGen Co., Ltd. (RemeGen Biosciences)
- Roche Holding AG
- Seagen, Inc. (Seattle Genetics, Inc.)
- Takeda Pharmaceutical Co. Ltd.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/antibody-drug-conjugates-market/
Related publications:
